ArticleClinical proteomics2026
Calcium-related genes predict prognosis, immune characteristics, and response to immunotherapy in LUAD patients.
Article in Clinical proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is a common subtype of lung cancer with a dismal prognosis and a lack of effective biomarkers at an early stage. Calcium plays a crucial role in immunomodulation and immunotherapy, and can effectively predict the prognosis of tumors. This study aimed to probe into the potential value of calcium-related genes (CRGs) in the prognosis of LUAD.
methodsRNA sequencing data, somatic mutation data, and demographic and clinical data of LUAD were collected from the TCGA database. GSE31210 data were collected from the GEO database, and data on CRGs were from GeneCards. Univariate, LASSO, multivariate Cox regression analyses, Kaplan-Meier survival analysis, ROC curve analysis, gene set enrichment analysis (GSEA), and other methods were employed to establish the prediction model and validate and annotate the functions. The tumor immune microenvironment in different risk groups was evaluated using ESTIMATE, single-sample GSEA, and CIBERSORT algorithms. The immunophenoscore and tumor immune dysfunction and exclusion scores were examined to predict immunotherapy response sensitivity. Anti-tumor drugs were screened through correlation analysis and differential comparison.
resultsEight calcium-related biomarkers (GRIA1, BTK, CLCA1, PDGFB, S100P, TRPA1, F2RL1, FBN2) significantly associated with the prognosis of LUAD were identified. A reliable risk-scoring model was constructed and its capability was validated. Patients with LUAD with worse clinical features (advanced stage, higher tumor burden, and lymph node metastases) had higher riskscores and a worse prognosis. Patients in the low-risk (LR) group exhibited a strong immune response, especially significantly increased mast cells, B cells, and Tfh cells. The high-risk (HR) group exhibited enrichment of immunosuppressive cells (e.g., Tregs), suggesting that the LR group may benefit more from the immune checkpoint suppressive therapy. Moreover, we predicted the clinical potential of drug candidates such as Erlotinib, Afatinib, and Barasertib.
conclusionWe discovered that multiple CRGs were significantly associated with the survival of LUAD and were differentially expressed in LUAD. We created a risk model for prognosis prediction based on CRGs in LUAD, which can not only effectively predict prognosis but also reflect changes in the tumor immune microenvironment among different risk groups. These findings may be beneficial for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.